Search

Displaying results 1831 - 1840 of 8196 in total
  1. Drug

    Erfonrilimab

    go.drugbank.com/drugs/DB17446
    Investigational

    Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).

  2. Drug

    Gremubamab

    go.drugbank.com/drugs/DB15014
    Investigational

    Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).

  3. Drug

    Ponezumab

    go.drugbank.com/drugs/DB15135
    Investigational

    Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).

    Synonyms: PF-04360365
  4. Drug

    Activated charcoal

    go.drugbank.com/drugs/DB09278
    ApprovedInvestigational

    Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. … It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances

  5. Drug

    Fluticasone

    go.drugbank.com/drugs/DB13867
    ApprovedInvestigationalWithdrawn

    Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...

    Mixtures: Fludalt DUO 250/50mcg Inhalation Powder Hard CapsulesCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. … Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Nimacimab

    go.drugbank.com/drugs/DB15115
    Investigational

    Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)).

  8. Drug

    Zinc citrate

    go.drugbank.com/drugs/DB11154
    ApprovedInvestigational

    It is available as dietary supplements as a treatment of zinc deficiency and source of zinc, which is an essential trace element.

    Mixtures: Dialyvite Supreme D, Calcium, Magnesium, Zinc and D
  9. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. … Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.

    Synonyms: p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine